Deutsche Bank Ag\ Brainstorm Cell Therapeutics Inc. Transaction History

Deutsche Bank Ag\

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$2.81 - $4.23 $5,901 - $8,883	-2,100 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$3.01 - $4.01 $55,919 - $74,497	-18,578 Reduced 89.84%	2,100 $8,000
Q1 2021 May 13, 2021	SELL	$3.46 - $7.88 $1,975 - $4,499	-571 Reduced 2.69%	20,678 $79,000
Q4 2020 Feb 16, 2021	BUY	$3.99 - $17.73 $22,208 - $98,685	5,566 Added 35.49%	21,249 $96,000
Q3 2020 Nov 12, 2020	BUY	$11.19 - $16.92 $22,861 - $34,567	2,043 Added 14.98%	15,683 $265,000
Q2 2020 Aug 13, 2020	BUY	$4.42 - $12.66 $60,288 - $172,682	13,640 New	13,640 $153,000
Q1 2020 May 14, 2020	SELL	$4.01 - $8.88 $14,139 - $31,310	-3,526 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.62 - $4.29 $12,764 - $15,126	3,526 New	3,526 $15,000
Q2 2018 Aug 14, 2018	SELL	$3.12 - $5.19 $93,325 - $155,243	-29,912 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$3.01 - $3.77 $206,720 - $258,916	-68,678 Reduced 69.66%	29,912 $94,000
Q4 2017 Feb 14, 2018	BUY	$2.96 - $4.42 $223,965 - $334,434	75,664 Added 330.04%	98,590 $386,000
Q3 2017 Nov 14, 2017	BUY	$3.98 - $4.36 $91,245 - $99,957	22,926	22,926 $94,000

10.8M

160K

30.5K

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $83.2M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.